In pre-revenue biotechs, trial results and partner
Post# of 72440
(Total Views: 191)
Posted On: 07/10/2017 12:40:38 AM
In pre-revenue biotechs, trial results and partnerships are the major catalysts. Last year we saw the stock ran up to almost $2 in anticipation to the P P2a result. When management decided to run a P2b then look for a partner, some investors sold.
IPIX just didn't have a major catalyst for the past 12 months, but the second half will be a different story. We just saw the stock ran up from the 60s to over $1 in anticipation to the B-UP result. I bet we'll see a much bigger run-up in anticipation to the P P2b result, especially if the interim analysis is positive.
No doubt SP manipulations are going on daily. I know you watch them closely. The shorts are betting against the science, not smart considering Dr. Menon's track record.
IPIX just didn't have a major catalyst for the past 12 months, but the second half will be a different story. We just saw the stock ran up from the 60s to over $1 in anticipation to the B-UP result. I bet we'll see a much bigger run-up in anticipation to the P P2b result, especially if the interim analysis is positive.
No doubt SP manipulations are going on daily. I know you watch them closely. The shorts are betting against the science, not smart considering Dr. Menon's track record.
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼